Please assess the completion status of the following clinical trial:

Trial Title: Effect of Cequa™ in Subjects With Dry Eye Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female subjects with a history of bilateral dry eye disease for a period of at least 3 months.~2. Aged of at least 18 years.~3. Subjects with total corneal fluorescein staining ≥6 or corneal fluorescein staining in an individual zone ≥2 as per National Eye Institute Grading Scale.~4. Subjects with modified symptom assessment in dry eye global symptom score, ≥40 using visual analogue scale.~5. Subjects with best-corrected visual acuity 20/200 or better in both eyes at the Screening/Baseline visit~Exclusion Criteria:~1. Subjects who have used cyclosporin 0.05% ophthalmic emulsion in both eyes for less than 3 months prior to the Screening/Baseline visit.~2. Subjects with history of treatment failure with cyclosporin 0.05% ophthalmic emulsion.~3. Subjects who have active seasonal and/or perennial allergic conjunctivitis in either eye.~4. Subjects who had already Use initiated any systemic or topical ocular medication.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CequaTM (Cyclosporine 0.09%) ophthalmic solution (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).